$11.19
0.423.9%
Last update: Oct 23, 11:32 AM
SANTEN PHARM CO UNSP/ADR by Santen Pharmaceutical Co., Ltd.
SNPHYOTCPK
SANTEN PHARM CO UNSP/ADR by Santen Pharmaceutical Co., Ltd. (SNPHY) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
SANTEN PHARM CO UNSP/ADR by Santen Pharmaceutical Co., Ltd. (SNPHY) last issued guidance on February 6, 2025 for fiscal year 2024. The company guided earnings per share in the range of $0.77 - $0.77, compared to a consensus EPS estimate of . SANTEN PHARM CO UNSP/ADR by Santen Pharmaceutical Co., Ltd. also guided revenue in the range of $1.98B - $1.98B for the period.
Compared to prior guidance, SANTEN PHARM CO UNSP/ADR by Santen Pharmaceutical Co., Ltd. raised its revenue forecast from a prior range of $1.93B - $1.93B.
SANTEN PHARM CO UNSP/ADR by Santen Pharmaceutical Co., Ltd. has issued 3 guidance updates between November 8, 2022 and February 6, 2025. During this period, the company raised its outlook 1 time and lowered it 1 time, providing investors with insight into management's evolving expectations.
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.12 | — | — | — |
| Actual | $0.11 | $0.09 | $0.18 | $0.34 |
| Surprise | -8.33% | — | — | — |
| Revenue | ||||
| Estimate | $418.8M | $530.2M | $530.2M | — |
| Actual | $431.3M | $515.2M | $473.2M | $419.7M |
| Surprise | +3.00% | -2.83% | -10.8% | — |
| Metric | Q2 '26E | Q3 '26E |
|---|---|---|
| Earnings Per Share (Non-GAAP) | ||
| Consensus | $0.28 | $0.18 |
| Revenue | ||
| Consensus | $450.1M | $490.0M |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q1 | Aug 6, 2026 | $0.11 | $0.12 | -8.33 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q1 | Aug 6, 2026 | $431.33M | $418.77M | 3.00 % |
| Q4 | May 14, 2026 | $515.18M | $530.21M | -2.83 % |
| Q3 | Feb 5, 2026 | $473.16M | $530.21M | -10.8 % |
